

# UHL Research and Innovation: Quarterly Trust Board Report October 2017

Author: Nigel Brunskill Sponsor: Andrew Furlong

Trust Board paper K

## Executive Summary

### Context

UHL is a Trust active in Research and Innovation (R&I). This report describes current R&I performance against metrics, projects under development, new challenges and potential threats.

### Questions

1. Is UHL performing well in the delivery of quality research at expected volume?
2. Are large projects planned with appropriate partners and managed appropriately?
3. Are upcoming challenges understood?

### Conclusion

1. UHL performs well in delivering high quality research as judged by NIHR and LCRN data, recruitment remains under continuous scrutiny.
2. A larger number of large projects are in development, some being close to start date. There is a wide range of NHS and Academic partner engagement.
3. A number of challenges are recognised and planning is in place to mitigate risks.

### Input Sought

Report is presented for information and assurance.

# For Reference

Edit as appropriate:

1. The following objectives were considered when preparing this report:

Safe, high quality, patient centred healthcare	[Yes]
Effective, integrated emergency care	[Yes]
Consistently meeting national access standards	[Not applicable]
Integrated care in partnership with others	[Yes]
Enhanced delivery in research, innovation & ed'	[Yes]
A caring, professional, engaged workforce	[Yes]
Clinically sustainable services with excellent facilities	[Yes]
Financially sustainable NHS organisation	[Yes]
Enabled by excellent IM&T	[Yes]

2. This matter relates to the following governance initiatives:

Organisational Risk Register	[Yes]
Board Assurance Framework	[Yes]

3. Related Patient and Public Involvement actions taken, or to be taken: [Insert here]

4. Results of any Equality Impact Assessment, relating to this matter: n/a

5. Scheduled date for the next paper on this topic: [TB January 2018]

6. Executive Summaries should not exceed 2 pages. [My paper does comply]

7. Papers should not exceed 7 pages. [My paper does comply]

# UHL R&I Quarterly Trust Board Report October 2017

## 1. Introduction

This report describes current R&I performance against metrics, projects under development, new challenges and potential threats.

## 2. Research Performance

The activity of UHL in initiating and delivering clinical research is performance monitored by both the NIHR Central Commissioning Facility (NIHR CCF) and the East Midlands Clinical Research Network (EM CRN). In turn the UHL R&I Office reports research CMG level activity and performance to each CMG via the R&I Executive Committee.

### 2.1 NIHR CCF

NIHR league tables (<http://www.nihr.ac.uk/research-and-impact/nhs-research-performance/league-tables/>) published in The Guardian show that for 15/16 UHL was the 6<sup>th</sup> highest recruiting trust in England. Equivalent figures are not yet available for 16/17.

UHL is also judged by its performance in initiating and delivering clinical trials to time and target. In Q1 2017/18 this figure has been excellent and represents a sustained improvement. Overall in terms of both initiating (6<sup>th</sup> place) and delivering (15<sup>th</sup> place) research, UHL remains ranked in League 1 (of 7) by NIHR.

### 2.2. EM CRN

Recruitment into portfolio clinical trials for 16/17 was approximately 20% lower than the same period in 15/16. UHL R&I has analysed recruitment and established an action plan to actively manage for 17/18. The UHL R&I team have had weekly meetings with EM CRN to actively manage performance and delivery into all portfolio studies.

The latest data available from EM CRN show that 4426 participants have been recruited into 220 open portfolio studies so far at UHL for 17/18. This is slightly ahead of the same stage in 16/17 and UHL remains the highest recruiting Trust in the East Midlands.

## 3. New Projects Underway

### 3.1 Adult and Children's Research Space

After a refurbishment supported by charitable and research funds, and a contribution from the Trust, the Children's Research Space officially opened at LRI in June 2017 with wide media coverage. There is now a wonderful Research Space at LRI (Balmoral level 0) with adjacent adult and children's facilities.

The Research Space Pharma Launch will take place in November 2017. A Clinical Lead for the Adult Research Space is soon to be appointed.

### 3.1 NIHR Leicester BRC, NIHR Leicester CRF and Experimental Cancer Medicine Centre (ECMC).

These major elements of NIHR funded infrastructure will commenced their new activities from 1<sup>st</sup> April 2017. A new UHL structure chaired by Director of R&I – NIHR Integrated Operations Group (NIOG) – will support the efficient functioning of all elements of NIHR infrastructure at UHL.

### 3.2 100,000 Genomes Project

UHL is recruiting above trajectory to rare diseases and also doing well in cancer recruitment. As yet no results have been returned, but clinical resource will be required for interpretation and communication of findings to patients.

## 4. Projects in Development

### 4.1. Bioinformatics

UHL has supported a University of Leicester bid to become a substantive site of the UK Farr Institute for Health & Biomedical Informatics research.

### 4.2 Senior NIHR Appointments

UHL and UoL will jointly support application from several senior clinical academics to become either NIHR Senior Investigators or NIHR Professors in the upcoming application rounds.

### **5. UHL/UoL Joint Strategy**

A 5 year joint UHL/UoL strategy is a supporting objective to the UHL Quality Commitment. This has been developed and approved by the UHL Executive Strategy Board and the UoL College of Life Sciences Leadership Team..

### **6. Innovation/Enterprise Activities**

We are working with Leicester Precision Medicine Institute and the Healthcare Innovation Hub Medipex to commercialise the Stent Project and NeedleGuide – a device for safe placement of needles and cannulae.

### **7. New/Existing Challenges**

6.1. Delivery of 100,000 Genome Project.

Genomics team working with relevant clinical specialities to facilitate recruitment. The major upcoming challenge is mainstreaming genomic medicine into clinical practice.

6.3. Hope Unit at Glenfield

Efforts continue to identify suitable space for Hope Unit at Glenfield Hospital

**Nigel Brunskill – Director of Research & Innovation**

Sept 2017